Re-engineering a neuroprotective, clinical drug as a procognitive agent with high in vivo potency and with GABAA potentiating activity for use in dementia
Crossref DOI link:
Update policy: https://0-doi-org.brum.beds.ac.uk/10.1007/SPRINGER_CROSSMARK_POLICY
Lee, Sue H.
Asghodom, Rezene T.
Aissa, Manel Ben
Pepperberg, David R.
Thatcher, Gregory R. J.
Funding for this research was provided by:
NIH Clinical Center (U01 AG031294, EY016094)
Alzheimer's Drug Discovery Foundation
Text and Data Mining valid from 2015-10-19
Version of Record valid from 2015-10-19
25 June 2015
7 October 2015
19 October 2015